Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Closes $3bn Deal For Viatris Biosimilars

Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation

Executive Summary

Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.

You may also be interested in...



Viatris Is ‘Not Walking Away’ From Generics

After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.

In Quick Succession: Wave Of New Leaders Could Reshape Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

Three Filings Planned, Two Others On Track – But No Names From Viatris

Viatris’ CEO-in-waiting Scott Smith introduced himself during Viatris’ year-end earnings call.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel